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Background: Although, in Western countries, oxaliplatin-based regimens have been established as a gold standard
treatment for patients with stage III or high risk stage II colon cancer after curative resection, in Japan
fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings
in patients with stage III colon cancer. S-1, an oral preparation evolved from uracil and tegafur, has equivalent
efficacy to uracil and tegafur/leucovorin for treating patients with advanced colorectal cancer and might be a
suitable regimen in an adjuvant setting. However, the completion rate of the standard six-week cycle of the S-1
regimen is poor and the establishment of an optimal treatment schedule is critical. Therefore, we will conduct a
multicenter randomized phase II trial to compare six-week and three-week cycles to establish the optimal schedule
of S-1 adjuvant therapy for patients with stage III colon cancer after curative resection.
Methods/Design: The study is an open-label, multicenter randomized phase II trial. The primary endpoint of this
study is three-year disease-free survival rate. Secondary endpoints are the completion rate of the treatment, relative
dose intensity, overall survival, disease-free survival, and incidence of adverse events. The sample size was 200,
determined with a significance level of 0.20, power of 0.80, and non-inferiority margin of a 10% absolute difference
in the primary endpoint.
Discussion: Although S-1 has not been approved yet as a standard treatment of colon cancer in an adjuvant
setting, it is a promising option. Moreover, in Japan S-1 is a standard treatment for patients with stage II/III gastric
cancer after curative resection and a promising option for patients with colorectal liver metastases in an adjuvant
setting. However, a six-week cycle of treatment is not considered to be the best schedule, and some clinicians use
a modified schedule, such as a three-week cycle to keep a sufficient dose intensity with few adverse events.
Therefore, it will be useful to determine whether a three-week cycle has an equal or greater efficacy and tolerance
to side-effects compared with the standard six-week cycle schedule, and thus may be the most suitable treatment
schedule for S-1 treatment.
Trial registration: The University Hospital Medical Information Network (UMIN) Clinical Trials Registry
UMIN000006750.
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In Japan, colorectal cancer remains the second most com-
mon cancer in both genders and the most common cause
of cancer mortality in women [1]. The rate of recurrence of
stage III colorectal cancer is reportedly 30.8% [2], and adju-
vant chemotherapy is important in the treatment of stage
III cancer after curative resection. In Western countries,
oxaliplatin (Ox)-based regimens in addition to fluorouracil
(FU) and leucovorin (LV) (FOLFOX (Ox + FU + LV),
FLOX (Ox + FU(, or XELOX (Ox + capecitabine)) have
been established as the gold standard adjuvant chemothe-
rapy for stage III colon cancer based on the results of three
large randomized controlled phase III studies conducted
after 2000 [3-5]. However, favorable results using an
FU-based regimen without Ox were reported in a
Japanese randomized controlled study (JCOG 0205)
[6]. This study compared uracil and tegafur (UFT)/LV
with 5-FU/LV as an adjuvant chemotherapy for patients
with stage III colon cancer and demonstrated that the
three-year disease-free survival (DFS) was 77.8% in the
UFT/LV arm and 79.3% in the 5-FU/LV arm, respectively.
This result was equal to the experimental arm of the MO-
SAIC trial using Ox (72.2% in stage III patients only) [3],
the NSABP C-07 trial (71.8% including stage II patients) [4]
and the XELOXA trial (70.9%) [5]. Therefore, the FU-based
regimen has been widely accepted as an adjuvant chemo-
therapy regimen for stage III colon cancer in Japan, and the
Japanese guidelines recommend 5-FU/LV, UFT/LV and
capecitabine as equal treatments to FOLFOX [2].
Oral FU is an effective, better tolerated, and convenient
chemotherapy regimen compared to Ox-based regimens,
as it does not require the use of a central infusion port
system and there is less need to visit the outpatient clinic.
Therefore, oral FU is a valuable treatment regimen for
both patients and medical staffs. The equality of UFT/LV
or capecitabine to 5-FU/LV has already been confirmed in
large randomized trials [7,8]. S-1 (TS-1, Taiho Pharma-
ceutical, Tokyo, Japan) is an oral preparation evolved from
UFT, which combines tegafur (a prodrug that is converted
by cells to fluorouracil), gimeracil (an inhibitor of dihydro-
pyrimidine dehydrogenase, which degrades fluorouracil),
and oteracil (which inhibits the phosphorylation of fluo-
rouracil in the gastrointestinal tract, thereby reducing the
gastrointestinal toxic effects of fluorouracil) at a molar
ratio of 1:0.4:1. Two Japanese phase II trials of S-1 mono-
therapy for chemotherapy-naïve patients with metastatic
colorectal cancer showed that the response rates were
35.5% and 39.5%, similar to the results from the joint
study of UFT/LV in the United States and Japan (36.4% in
Japan and 34.1% in the United States). In addition, the effi-
cacy of S-1 in an adjuvant setting has been demonstrated
in a Japanese phase III trial in patients with stage II or III
gastric cancer (ACTS-GC trial) [9]. Currently, two rando-
mized clinical trials are ongoing in Japan to compare theeffectiveness of S-1 as an adjuvant chemotherapy with that
of UFT/LV or capecitabine in patients with stage III colon
cancer [10,11].
The standard schedule of S-1 monotherapy is an oral
six-week cycle (four-weeks administration followed by
two-weeks rest). However, the completion rate of sche-
duled treatment in the ACTS-GC trial was reported to be
65.8% [9], which is relatively low, and, moreover, some
patients received a modified schedule, such as a three-
week cycle (two-weeks administration followed by a one-
week rest). Some studies indicated that patients who
discontinued treatment early in the adjuvant setting for
colon cancer showed poor survival [12,13]. Therefore, it is
an urgent necessity to establish the optimal treatment
schedule in order to reduce the withdrawal rate of patients
receiving S-1 therapy. Only one randomized phase II
trial, in which a three-week cycle was compared with
a standard six-week cycle has been published. An increase
in compliance and a decrease in toxicity was observed in
the patients treated with a three-week cycle, and this
suggested its use for patients with stage III/IV squamous
cell carcinoma of the head and neck after definitive treat-
ment [14]. In this trial, the completion rate along the
planned schedule and dose was 40% and 20% in patients
treated with a three-week cycle and a six-week cycle and
severe adverse grade 3 events were observed in 14% and
27%, respectively.
Based on these findings, we designed the present rando-
mized phase II trial to compare a six-week cycle with a
three-week cycle, and to establish the optimal schedule of




The aim of this study is to determine the optimal sche-
dule of S-1 adjuvant chemotherapy for patients with
stage III colon cancer after curative resection.
Study design
The study is an open-label, multicenter randomized
phase II trial, in which participating institutions include
thirteen specialized centers in Japan as of August 2012.
Participating institutions are listed in Additional file 1:
Appendix A.
Ethical considerations and registration
This study has been conducted in accordance with the
Declaration of Helsinki and Ethics Guidelines for Clinical
Research by the Ministry of Health, Labor, and Welfare,
Japan. Informed consent will be provided for all patients
before registration. The trial was approved by the ethics
committee of each institution involved in the study. This
study was registered at the UMIN Clinical Trial Registry





The primary endpoint with respect to efficacy is three-
year DFS rate. Secondary endpoints are completion rate
of the treatment, relative dose intensity (RDI), overall
survival (OS), DFS and incidence of adverse events
defined by Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0.
Eligibility criteria
Surgery has to have been performed within eight weeks
before induction of the chemotherapy. The primary tumor
is staged according to the 7th edition, revised version of
the Japanese classification of colorectal carcinoma [15].
Inclusion criteria
Prior to enrollment in the study, patients must fulfill all of
the following criteria: histologically confirmed stage III
colon adenocarcinoma (including rectosigmoid cancer);
R0 resection for primary tumor; no distant metastases
evident on chest, abdominal and pelvic computed tomo-
graphy (CT); no previous treatment with chemotherapy or
radiotherapy for cancer; no current therapeutic treatment
with anticoagulants; Eastern Cooperative Oncology Group
performance status of 0 to 1; age 20 or older; capable of
oral drug intake; and adequate hematological, liver and
renal functions as below.
i) White blood cell count of ≥3,500/mm3 and
<12,000/mm3.
ii) Neutrophil count of ≥3,500/ mm3.
iii) Hemoglobin of ≥9.0 g/dL.
iv) Platelets of ≥100,000/mm3.
v) Total bilirubin of ≤2.0 mg/dL.
vi) AST of ≤100 IU/L and ALT of ≤ 00 IU/L.
vii) Creatinine level of ≤1.2 mg/dL.
viii) Creatinine clearance of ≥60 mL/minute.
Patients have been informed of the investigational nature
of the study and have provided their written informed
consent before registration.
Exclusion criteria
Patients may be excluded for any of the following reasons:
a synchronous or metachronous active malignancy; serious
co-morbidities, such as pulmonary fibrosis or interstitial
pneumonia, uncontrollable peptic ulcer disease, poorly
controlled diabetes mellitus, severe cardiovascular disease
(myocardial infarction, uncontrolled arrhythmia, uncon-
trolled hypertension) or another serious medical condition;
pregnancy or breast-feeding; diarrhea or a peripheralneuropathy greater than Grade 1; or a previous history of
severe drug-induced allergy.
Patient registration and randomization
The participating investigators send an eligibility criteria
report to the Data Center and the patients are randomly
assigned, in a 1:1 ratio, to either one of the two groups of
the S-1 regimen with the different schedules. Computer-
generated randomization is performed by minimization
methods, stratified by lymph node metastasis (pN1 versus
pN2 or pN3) by an institution at a non-profit organization,
Medical Support Aichi, Nagoya, Japan. Patient registration
began on October 2011 and is to continue for three years.
Treatment
The patients are randomized to either a six-week cycle
(arm A) or a three-week cycle (arm B) of the S-1 regimen.
Arm A: six-week cycle
S-1 is given orally at the respective dose for 28 days,
followed by a 2-week rest period. Patients are assigned on
the basis of body surface area (BSA) to receive one of the
following doses twice daily, after breakfast and dinner:
BSA < 1.25 m [2], 40 mg; 1.25≤BSA< 1.50 m [2], 50 mg;
and BSA ≥ 1.50 m [2], 60 mg.
Arm B: three-week cycle
S-1 is given orally at the same dose for 14 days, followed
by a 1-week rest period.
If patients had hematologic toxicities of grade 3 or 4
(highest possible grade) or non-hematologic toxicities of
grade 2 or higher, their daily dose will be reduced, from 120
mg to 100 mg, 100 mg to 80 mg, or 80 mg to 50 mg. Treat-
ment will be discontinued in patients who had disease re-
currence or adverse reactions unable to be controlled by
dose modification or temporary withdrawal of S-1. Patients
whose toxicities necessitated a rest period of more than
two weeks will also be withdrawn from treatment.
Follow-up
After completion of scheduled treatment, the patients
are followed-up until recurrence, other malignancies
developed or death is proven, over a period of at least
three years. All patients are required to take a blood test,
and carcinoembryonic antigen (CEA) and carbohydrate
antigen 19–9 (CA 19–9) as tumor marker tests at three-
month intervals, and chest, abdominal and pelvic CT at
six-month intervals during the first three years. All the
patients will be evaluated every three months for the
first three years after surgery and every six months for
the next two years. The evaluation includes a physical
examination, a complete blood count, blood chemical
tests, and serum tumor markers. Computed tomography
will be performed every six months.
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This study was based on the hypothesis that a three-week
cycle S-1 regimen would be non-inferior to a six-week cycle
S-1 for the primary endpoint, with the use of a prespecified
non-inferiority margin. The non-inferiority margin was an
absolute difference of 10% in the primary endpoint between
groups. To test for non-inferiority with a background
three-year DFS rate of 75% and an absolute non-inferiority
margin of 10%, a total sample size of 200 patients was
required for 80% power at a significance level of 20%.
Statistical analysis
The analysis population for efficacy is the full analysis
set. For analysis of the primary endpoint, we estimated
the confidence interval (CI) of the hazard ratio using the
Cox regression model with a significance level of 20%.
Non-inferiority of a three-week cycle S-1 regimen will
be claimed if the estimated upper limit of the hazard
ratio did not exceed 1.5, which is equivalent to an absolute
difference of 10%.
Discussion
This study is the first randomized trial to investigate the
optimal schedule of S-1 therapy for patients with stage III
colon cancer. Although S-1 has not been approved yet as
a standard treatment in an adjuvant setting, it is a promi-
sing option. Moreover, S-1 is a gold standard treatment
for patients with stage II/III gastric cancer after curative
resection in Japan [9] and is a promising option for
patients with colorectal liver metastases in an adjuvant
setting. Currently, however, a six-week cycle is not thought
to be the best schedule, and some clinicians have selected a
modified schedule, such as the three-week cycle as it main-
tains a sufficient dose intensity with few adverse events. It
is extremely valuable to show that a three-week cycle has
an equal or greater efficacy and tolerance to side-effects
compared with a standard six-week cycle schedule and,
therefore, may be the most suitable treatment schedule for
the S-1 regimen.
Trial status
The trial was initiated in October 2011. By 30 July 2012,
38 patients had been registered and randomized.
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